Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer

PURPOSE: Neoadjuvant chemotherapy (NAC) is less effective for luminal breast cancer because luminal breast cancer has a lower rate of pathological complete response (pCR) after NAC than human epidermal growth factor receptor 2 (HER2)-type and triple-negative breast cancer (TNBC). We investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyung Suk, Yoo, Tae Kyung, Park, Woo Chan, Chae, Byung Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769389/
https://www.ncbi.nlm.nih.gov/pubmed/31598341
http://dx.doi.org/10.4048/jbc.2019.22.e35

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769389/
https://www.ncbi.nlm.nih.gov/pubmed/31598341
http://dx.doi.org/10.4048/jbc.2019.22.e35

Ejemplares similares